PDCD1 and head and neck squamous cell carcinoma: The present study sought to identify biomarkers that predict the therapeutic response to the anti-PD-1 antibody, nivolumab, based on a multicenter retrospective study to select the best course of treatment for patients with R/M HNSCC.